Format

Send to:

Choose Destination
See comment in PubMed Commons below
Haematologica. 2015 Mar;100(3):385-91. doi: 10.3324/haematol.2014.115204. Epub 2014 Nov 14.

Lenalidomide and dexamethasone for acute light chain-induced renal failure: a phase II study.

Author information

  • 1Department of Medicine I, Wilhelminenspital, Vienna, Austria Heinz.ludwig@wienkav.at.
  • 2Department of Medicine I, Wilhelminenspital, Vienna, Austria.
  • 3Department of Internal Medicine 4, Hospital Wels-Grieskirchen, Austria.
  • 4University Hospital, Brno, Czech Republic.
  • 5Department of Internal Medicine, Hospital Elisabethinen, Linz, Austria.
  • 6Department of Internal Medicine III, Hospital Salzburg, Austria.
  • 7Department of Hemato-Oncology, University Clinic Leipzig, Germany.

Abstract

We prospectively evaluated the activity and tolerance of lenalidomide-dexamethasone in 35 patients with acute light chain-induced renal failure. The lenalidomide dose was adapted to the estimated glomerular filtration rate and dexamethasone was given at high dose in cycle one and at low dose thereafter. Four patients died within the first two cycles, and five discontinued therapy leaving 26 patients for the per-protocol analysis. Responses were observed in 24/35 (68.6%) patients of the intent-to-treat population. Complete response was noted in seven patients (20%), very good partial response in three patients (8.6%), partial response in 14 patients (40%), and minimal response in one patient (2.9%). Renal response was observed in 16 (45.7%) patients: five (14.2%) achieved complete, four (11.4%) partial and seven (20%) minor renal responses. Five of 13 patients who were dialysis dependent at baseline became dialysis independent. The median time to myeloma and to renal response was 28 days for both parameters, while the median time to best myeloma and best renal response was 92 and 157 days, respectively. The median estimated glomerular filtration rate increased significantly in patients with partial response or better from 17.1 mL/min at baseline to 39.1 mL/min at best response (P=0.001). The median progression-free and overall survival was 5.5 and 21.8 months, respectively, in the intent-to-treat population and 12.1 and 31.4 months, respectively, in the per-protocol group. Infections, cardiotoxicity, anemia and thrombocytopenia were the most frequent toxicities. In conclusion, the lenalidomide-dexamethasone regimen achieved rapid and substantial myeloma and renal responses. The trial was registered under EUDRACT number 2008-006497-15.

Copyright© Ferrata Storti Foundation.

PMID:
25398836
[PubMed - indexed for MEDLINE]
PMCID:
PMC4349278
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Write to the Help Desk